Partner at Vivo Capital
View Live Interactive Profile →Kevin Dai is listed as a Partner on the Vivo Capital investment team. He holds a Pharm.D from the Ernest Mario School of Pharmacy at Rutgers University and is a board certified oncology pharmacist. He completed an internal medicine residency at the University of Chicago Medical Center and an oncology residency at Memorial Sloan Kettering Cancer Center, where he then spent three years as a Clinical Oncology Pharmacy Specialist in hematology providing direct patient care and managing active clinical trials in the leukemia department. He subsequently worked at Canaccord Genuity as an equity research associate covering biotechnology and specialty pharmaceutical companies, and earlier interned at Merck & Co. in the ion channel department. He was quoted as a Managing Director of Vivo in the firm's 7 May 2025 announcement of the close of the third cycle of the Vivo Opportunity Fund, and his individual profile page still carries the title Managing Director, while the current team page lists him as Partner; the team page title is used here.